The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was $31.86 for the day, down -2.54% from the previous closing price of $32.69. In other words, the price has decreased by -$2.54 from its previous closing price. On the day, 0.59 million shares were traded. NAMS stock price reached its highest trading level at $32.83 during the session, while it also had its lowest trading level at $31.47.
Ratios:
Our analysis of NAMS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.57 and its Current Ratio is at 12.57. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On August 25, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $45.
On July 17, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $27.Goldman initiated its Neutral rating on July 17, 2025, with a $27 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 05 ’26 when Kastelein Johannes Jacob Piete sold 6,000 shares for $33.25 per share. The transaction valued at 199,500 led to the insider holds 73,481 shares of the business.
Kooij Louise Frederika sold 2,647 shares of NAMS for $88,013 on Jan 05 ’26. The Chief Accounting Officer now owns 12,353 shares after completing the transaction at $33.25 per share. On Jan 05 ’26, another insider, Somaiya Mayur Ian, who serves as the Chief Financial Officer of the company, sold 5,118 shares for $33.25 each. As a result, the insider received 170,174 and left with 32,882 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 3612631040 and an Enterprise Value of 2909950976. For the stock, the TTM Price-to-Sale (P/S) ratio is 102.52 while its Price-to-Book (P/B) ratio in mrq is 4.95. Its current Enterprise Value per Revenue stands at 82.568 whereas that against EBITDA is -14.355.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.07, which has changed by 0.36208332 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $42.00, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is -12.83%, while the 200-Day Moving Average is calculated to be 20.02%.
Shares Statistics:
NAMS traded an average of 1.06M shares per day over the past three months and 818800 shares per day over the past ten days. A total of 113.17M shares are outstanding, with a floating share count of 80.49M. Insiders hold about 29.02% of the company’s shares, while institutions hold 67.14% stake in the company. Shares short for NAMS as of 1767139200 were 6213363 with a Short Ratio of 5.84, compared to 1764288000 on 6677161. Therefore, it implies a Short% of Shares Outstanding of 6213363 and a Short% of Float of 6.529999999999999.
Earnings Estimates
The market rating for NewAmsterdam Pharma Company NV (NAMS) is a result of the insights provided by 13.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.31 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.01 and -$1.58 for the fiscal current year, implying an average EPS of -$1.33. EPS for the following year is -$1.5, with 11.0 analysts recommending between -$1.14 and -$2.08.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $45.34M, while the lowest revenue estimate was $19.13M, resulting in an average revenue estimate of $23.36M. In the same quarter a year ago, actual revenue was $43.39M
